These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15921362)

  • 1. [Cardiovascular drugs.12/12. Oral platelet inhibitors].
    Medjoub M; Limat S
    Soins; 2005 May; (695):53-4. PubMed ID: 15921362
    [No Abstract]   [Full Text] [Related]  

  • 2. Putting a stop to thrombi.
    Palatnik A
    Nursing; 2007; 37 Suppl Cardiac():2-6. PubMed ID: 18075484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulants and antiplatelet drugs.
    Gallus AS
    Med J Aust; 1994 Jan; 160(2):78-82. PubMed ID: 8309373
    [No Abstract]   [Full Text] [Related]  

  • 4. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology.
    Kuliczkowski W; Witkowski A; Polonski L; Watala C; Filipiak K; Budaj A; Golanski J; Sitkiewicz D; Pregowski J; Gorski J; Zembala M; Opolski G; Huber K; Arnesen H; Kristensen SD; De Caterina R
    Eur Heart J; 2009 Feb; 30(4):426-35. PubMed ID: 19174428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
    Gurbel PA
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic, antiinflammatory drugs? Arguments against.
    Weber AA; Hohlfeld T; Harder S
    Thromb Haemost; 2006 Oct; 96(4):413-6. PubMed ID: 17003916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis, causes, relevance of a complex phenomenon. Resistance to aspirin and clopidogrel].
    Mani H; Lindhoff-Last E
    Pharm Unserer Zeit; 2009; 38(4):342-50. PubMed ID: 19572355
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug-eluting stent pathology--should we still be cautious?
    Nakazawa G; Finn AV; Virmani R
    Nat Clin Pract Cardiovasc Med; 2008 Jan; 5(1):1. PubMed ID: 18094669
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prescription, monitoring of antithrombotic treatment: 1--antiplatelet agents].
    Drouet L
    Rev Prat; 2007 Nov; 57(18):2045-50. PubMed ID: 18326440
    [No Abstract]   [Full Text] [Related]  

  • 11. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prescription and surveillance of antithrombotic agents. Part 2: antiplatelet agents].
    Lecompte T
    Rev Prat; 2004 Apr; 54(7):791-4. PubMed ID: 15253299
    [No Abstract]   [Full Text] [Related]  

  • 13. Thrombogenicity in patients with percutaneous coronary artery intervention and dual antiplatelet treatment.
    Kamphuisen PW
    Eur Heart J; 2008 Jul; 29(14):1699-700. PubMed ID: 18544543
    [No Abstract]   [Full Text] [Related]  

  • 14. [Various therapy options. Medical Chemistry of platelet aggregation inhibitors].
    Zettl H; Schubert-Zsilavecz M
    Pharm Unserer Zeit; 2009; 38(4):314-9. PubMed ID: 19572349
    [No Abstract]   [Full Text] [Related]  

  • 15. [The anti-platelet aggregation drugs: new approaches based on snake venom polypeptides].
    Marrakchi N; Guermazi S; El Ayeb M
    Arch Inst Pasteur Tunis; 1997; 74(1-2):9-15. PubMed ID: 15945171
    [No Abstract]   [Full Text] [Related]  

  • 16. [Antiaggregant drugs: their pharmacology, mechanism of action and the interpretation of large trials].
    Cattaneo M; Mannucci PM
    G Ital Cardiol; 1990 Jul; 20(7):661-9. PubMed ID: 2147159
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel.
    van Werkum JW; Topcu Y; Postma S; Kelder JC; Hackeng CM; ten Berg JM; Verheugt FW
    Thromb Haemost; 2008 Mar; 99(3):637-9. PubMed ID: 18327417
    [No Abstract]   [Full Text] [Related]  

  • 18. Communicating the safety essentials of oral anticoagulant therapy.
    Lamarche K; Heale R
    Home Healthc Nurse; 2007; 25(7):448-56; quiz 457-8. PubMed ID: 17667004
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet inhibitors and monitoring platelet function: implications for bleeding.
    Shore-Lesserson L
    Hematol Oncol Clin North Am; 2007 Feb; 21(1):51-63. PubMed ID: 17258118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for antiplatelet targets and agents.
    Xiang YZ; Kang LY; Gao XM; Shang HC; Zhang JH; Zhang BL
    Thromb Res; 2008; 123(1):35-49. PubMed ID: 18571699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.